Connection

JAMES P ALLISON to T-Lymphocytes

This is a "connection" page, showing publications JAMES P ALLISON has written about T-Lymphocytes.
Connection Strength

4.556
  1. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 09; 8(9):1069-1086.
    View in: PubMed
    Score: 0.257
  2. Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA. 2015 Sep 15; 314(11):1113-4.
    View in: PubMed
    Score: 0.210
  3. The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61.
    View in: PubMed
    Score: 0.204
  4. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol. 2011 Oct 01; 187(7):3459-65.
    View in: PubMed
    Score: 0.160
  5. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol. 2011 May 01; 186(9):5039-45.
    View in: PubMed
    Score: 0.155
  6. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499.
    View in: PubMed
    Score: 0.155
  7. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010 Aug 02; 207(8):1701-11.
    View in: PubMed
    Score: 0.147
  8. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev. 2009 May; 229(1):67-87.
    View in: PubMed
    Score: 0.135
  9. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008 Sep 01; 205(9):2125-38.
    View in: PubMed
    Score: 0.129
  10. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008 Aug; 224:141-65.
    View in: PubMed
    Score: 0.128
  11. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A. 2007 Nov 06; 104(45):17765-70.
    View in: PubMed
    Score: 0.122
  12. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5271-9.
    View in: PubMed
    Score: 0.121
  13. To be or not to be B7. J Clin Invest. 2006 Oct; 116(10):2590-3.
    View in: PubMed
    Score: 0.113
  14. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol. 2005 Sep; 130(6):809-24.
    View in: PubMed
    Score: 0.105
  15. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 Sep; 21(3):401-13.
    View in: PubMed
    Score: 0.098
  16. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther. 2004; 6(5):208-14.
    View in: PubMed
    Score: 0.097
  17. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10388-92.
    View in: PubMed
    Score: 0.091
  18. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3013-7.
    View in: PubMed
    Score: 0.082
  19. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002 Jan; 16(1):23-35.
    View in: PubMed
    Score: 0.081
  20. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
    View in: PubMed
    Score: 0.080
  21. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.071
  22. Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun; 9(3):396-404.
    View in: PubMed
    Score: 0.059
  23. T cell-mediated elimination of B7.2 transgenic B cells. Immunity. 1997 Mar; 6(3):327-39.
    View in: PubMed
    Score: 0.058
  24. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.056
  25. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
    View in: PubMed
    Score: 0.056
  26. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct; 7(5):682-6.
    View in: PubMed
    Score: 0.053
  27. Checkpoints. Cell. 2015 Sep 10; 162(6):1202-5.
    View in: PubMed
    Score: 0.052
  28. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
    View in: PubMed
    Score: 0.052
  29. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995 Jul; 16(7):306-10.
    View in: PubMed
    Score: 0.052
  30. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 09; 161(2):205-14.
    View in: PubMed
    Score: 0.051
  31. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015 05 21; 125(21):3335-46.
    View in: PubMed
    Score: 0.051
  32. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994 Jun; 6(3):414-9.
    View in: PubMed
    Score: 0.048
  33. Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. Reg Immunol. 1993 Nov-Dec; 5(6):332-8.
    View in: PubMed
    Score: 0.046
  34. Intrathymic differentiation of V gamma 3 T cells. J Exp Med. 1993 Jul 01; 178(1):309-15.
    View in: PubMed
    Score: 0.045
  35. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43.
    View in: PubMed
    Score: 0.043
  36. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992 Apr 16; 356(6370):607-9.
    View in: PubMed
    Score: 0.041
  37. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012 Feb 08; 482(7385):400-4.
    View in: PubMed
    Score: 0.041
  38. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A. 2012 Jan 17; 109(3):881-6.
    View in: PubMed
    Score: 0.041
  39. Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. Semin Immunol. 1991 Mar; 3(2):89-97.
    View in: PubMed
    Score: 0.038
  40. Introduction: gamma delta T cells--the 'other' T lymphocytes. Semin Immunol. 1991 Mar; 3(2):73-4.
    View in: PubMed
    Score: 0.038
  41. The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol. 1991; 9:679-705.
    View in: PubMed
    Score: 0.038
  42. The immunobiology of gamma delta+ T cells. Semin Immunol. 1990 Jan; 2(1):59-65.
    View in: PubMed
    Score: 0.035
  43. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature. 1989 Sep 07; 341(6237):60-2.
    View in: PubMed
    Score: 0.035
  44. Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. Eur J Immunol. 1989 May; 19(5):857-63.
    View in: PubMed
    Score: 0.034
  45. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20410-5.
    View in: PubMed
    Score: 0.033
  46. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature. 1988 Sep 29; 335(6189):443-5.
    View in: PubMed
    Score: 0.032
  47. Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. Proc Natl Acad Sci U S A. 1988 Feb; 85(4):1174-8.
    View in: PubMed
    Score: 0.031
  48. Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. Immunol Res. 1988; 7(4):292-302.
    View in: PubMed
    Score: 0.031
  49. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature. 1987 Nov 12-18; 330(6144):170-3.
    View in: PubMed
    Score: 0.030
  50. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007 Sep; 12(3):192-9.
    View in: PubMed
    Score: 0.030
  51. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 2006 Dec; 88(6):841-845.
    View in: PubMed
    Score: 0.028
  52. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. 1983. J Immunol. 2006 Mar 01; 176(5):2683-90.
    View in: PubMed
    Score: 0.027
  53. Molecular characterization of the murine T cell antigen receptor and associated structures. Fed Proc. 1985 Oct; 44(13):2870-3.
    View in: PubMed
    Score: 0.026
  54. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol. 2005 Oct 01; 175(7):4199-207.
    View in: PubMed
    Score: 0.026
  55. Identification of antigen receptor-associated structures on murine T cells. Nature. 1985 Mar 7-13; 314(6006):107-9.
    View in: PubMed
    Score: 0.025
  56. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173(10):6098-108.
    View in: PubMed
    Score: 0.025
  57. The murine T cell antigen receptor and associated structures. Immunol Rev. 1984 Oct; 81:145-60.
    View in: PubMed
    Score: 0.025
  58. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16; 22(13-14):1700-8.
    View in: PubMed
    Score: 0.024
  59. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood. 2004 Jun 15; 103(12):4594-601.
    View in: PubMed
    Score: 0.024
  60. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell. 1983 Oct; 34(3):739-46.
    View in: PubMed
    Score: 0.023
  61. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003 Jul; 4(7):670-9.
    View in: PubMed
    Score: 0.022
  62. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8.
    View in: PubMed
    Score: 0.021
  63. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood. 2002 Jun 15; 99(12):4509-16.
    View in: PubMed
    Score: 0.021
  64. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.020
  65. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.018
  66. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight. 2019 10 03; 4(19).
    View in: PubMed
    Score: 0.017
  67. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:147-164.
    View in: PubMed
    Score: 0.017
  68. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451.
    View in: PubMed
    Score: 0.015
  69. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med. 1997 Jul 21; 186(2):221-8.
    View in: PubMed
    Score: 0.015
  70. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802.
    View in: PubMed
    Score: 0.015
  71. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017 04 27; 8:15095.
    View in: PubMed
    Score: 0.015
  72. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
    View in: PubMed
    Score: 0.015
  73. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.015
  74. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
    View in: PubMed
    Score: 0.014
  75. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. Int Immunol. 1993 Nov; 5(11):1451-60.
    View in: PubMed
    Score: 0.012
  76. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8987-91.
    View in: PubMed
    Score: 0.011
  77. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med. 1993 Apr 01; 177(4):1061-70.
    View in: PubMed
    Score: 0.011
  78. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14.
    View in: PubMed
    Score: 0.008
  79. Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature. 1987 Dec 10-16; 330(6148):574-6.
    View in: PubMed
    Score: 0.008
  80. The gamma T-cell antigen receptor. J Clin Immunol. 1987 Nov; 7(6):429-40.
    View in: PubMed
    Score: 0.008
  81. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol. 1987; 5:503-40.
    View in: PubMed
    Score: 0.007
  82. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell. 1983 Nov; 35(1):295-302.
    View in: PubMed
    Score: 0.006
  83. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. Int Immunol. 1991 Apr; 3(4):385-93.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.